Captrust Financial Advisors bought a new stake in shares of Edwards Lifesciences Corp (NYSE:EW) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,810 shares of the medical research company’s stock, valued at approximately $204,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of EW. Bank of New York Mellon Corp boosted its position in shares of Edwards Lifesciences by 45.7% during the 4th quarter. Bank of New York Mellon Corp now owns 7,580,924 shares of the medical research company’s stock valued at $854,444,000 after acquiring an additional 2,377,444 shares during the last quarter. Atlantic Trust Group LLC boosted its position in shares of Edwards Lifesciences by 734.7% during the 3rd quarter. Atlantic Trust Group LLC now owns 914,989 shares of the medical research company’s stock valued at $100,018,000 after acquiring an additional 805,370 shares during the last quarter. Two Sigma Advisers LP boosted its position in shares of Edwards Lifesciences by 827.6% during the 4th quarter. Two Sigma Advisers LP now owns 855,189 shares of the medical research company’s stock valued at $96,388,000 after acquiring an additional 763,000 shares during the last quarter. Alliancebernstein L.P. boosted its position in shares of Edwards Lifesciences by 12.1% during the 4th quarter. Alliancebernstein L.P. now owns 6,259,771 shares of the medical research company’s stock valued at $705,539,000 after acquiring an additional 675,216 shares during the last quarter. Finally, Two Sigma Investments LP boosted its position in shares of Edwards Lifesciences by 488.1% during the 4th quarter. Two Sigma Investments LP now owns 708,644 shares of the medical research company’s stock valued at $79,871,000 after acquiring an additional 588,148 shares during the last quarter. Hedge funds and other institutional investors own 82.86% of the company’s stock.
In other news, VP Jean-Luc M. Lemercier sold 5,633 shares of Edwards Lifesciences stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $136.29, for a total transaction of $767,721.57. Following the completion of the sale, the vice president now directly owns 44,298 shares in the company, valued at $6,037,374.42. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 3,750 shares of Edwards Lifesciences stock in a transaction on Monday, February 12th. The stock was sold at an average price of $127.54, for a total value of $478,275.00. Following the sale, the vice president now owns 19,608 shares of the company’s stock, valued at $2,500,804.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 165,603 shares of company stock valued at $20,186,132. Corporate insiders own 2.13% of the company’s stock.
Shares of Edwards Lifesciences Corp (NYSE EW) opened at $142.34 on Friday. The stock has a market capitalization of $29,613.34, a price-to-earnings ratio of 49.42, a P/E/G ratio of 2.07 and a beta of 0.56. Edwards Lifesciences Corp has a 52-week low of $91.30 and a 52-week high of $143.22. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.80 and a quick ratio of 1.41.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.91 by $0.03. The company had revenue of $888.50 million during the quarter, compared to the consensus estimate of $868.45 million. Edwards Lifesciences had a return on equity of 27.78% and a net margin of 18.11%. Edwards Lifesciences’s revenue was up 15.7% on a year-over-year basis. During the same period last year, the company earned $0.75 earnings per share. analysts anticipate that Edwards Lifesciences Corp will post 4.53 EPS for the current year.
Edwards Lifesciences announced that its board has authorized a stock repurchase program on Thursday, December 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its shares are undervalued.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.